Open AccessAre We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB
Author(s) -
Elisa H. Ignatius,
Susan Swindells
Publication year - 2020
Publication title -
current hiv/aids reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.135
H-Index - 56
eISSN - 1548-3576
pISSN - 1548-3568
DOI - 10.1007/s11904-020-00529-8
Subject(s) - medicine , tuberculosis , short course , latent tuberculosis , antiretroviral therapy , intensive care medicine , human immunodeficiency virus (hiv) , disease , directly observed therapy , drug , incidence (geometry) , immunology , mycobacterium tuberculosis , pediatrics , pharmacology , viral load , pathology , physics , optics
Despite broad uptake of antiretroviral therapy (ART), tuberculosis (TB) incidence and mortality among people with HIV remain unacceptably high. Short-course regimens for TB, incorporating both novel and established drugs, offer the potential to enhance adherence and completion rates, thereby reducing the global TB burden. This review will outline short-course regimens for TB among patients with HIV.